GT Biopharma, Inc. (GTBP)
0.3036
0.00 (0.00%)
USD |
NASDAQ |
Aug 25, 15:27
GT Biopharma PE Ratio
PE Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PE Ratio Data
| Date | Value |
|---|---|
| March 30, 2017 | 0.0199 |
| March 29, 2017 | 0.0194 |
| March 28, 2017 | 0.0199 |
| March 27, 2017 | 0.0193 |
| March 24, 2017 | 0.0234 |
| March 23, 2017 | 0.0265 |
| March 22, 2017 | 0.0296 |
| March 21, 2017 | 0.0353 |
| March 20, 2017 | 0.0364 |
| March 17, 2017 | 0.0221 |
| March 16, 2017 | 0.0274 |
| March 15, 2017 | 0.0324 |
| March 14, 2017 | 0.0302 |
| March 13, 2017 | 0.0361 |
| March 10, 2017 | 0.039 |
| March 09, 2017 | 0.0427 |
| March 08, 2017 | 0.0464 |
| March 07, 2017 | 0.0456 |
| March 06, 2017 | 0.0486 |
| March 03, 2017 | 0.0514 |
| March 02, 2017 | 0.0471 |
| March 01, 2017 | 0.0486 |
| February 28, 2017 | 0.0427 |
| February 27, 2017 | 0.0464 |
| February 24, 2017 | 0.0589 |
| Date | Value |
|---|---|
| February 23, 2017 | 0.06 |
| February 22, 2017 | 0.0633 |
| February 21, 2017 | 0.0633 |
| February 17, 2017 | 0.0668 |
| February 16, 2017 | 0.0612 |
| February 15, 2017 | 0.0648 |
| February 14, 2017 | 0.0649 |
| February 13, 2017 | 0.0736 |
| February 10, 2017 | 0.0809 |
| February 09, 2017 | 0.0868 |
| February 08, 2017 | 0.0883 |
| February 07, 2017 | 0.0953 |
| February 06, 2017 | 0.1082 |
| February 03, 2017 | 0.1102 |
| February 02, 2017 | 0.1089 |
| February 01, 2017 | 0.1177 |
| January 31, 2017 | 0.1119 |
| January 30, 2017 | 0.1148 |
| January 27, 2017 | 0.1186 |
| January 26, 2017 | 0.1207 |
| January 25, 2017 | 0.123 |
| January 24, 2017 | 0.1325 |
| January 23, 2017 | 0.1177 |
| January 20, 2017 | 0.1236 |
| January 19, 2017 | 0.1342 |
Price to Earnings Ratio (PE Ratio) Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PE Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 13.79 |
| Alnylam Pharmaceuticals, Inc. | 40.31 |
| Anika Therapeutics, Inc. | -- |
| Savara, Inc. | -- |
| Vericel Corp. | 93.00 |
PE Ratio Related Metrics
| Price to Book Value | 3.801 |
| Price | 0.3036 |
| Earnings Yield | -1.19K% |
| Market Cap | 13.56M |